Humana Coverage Deal: Recent chatter on X about Plus Therapeutics (PSTV) has been fueled by the company’s announcement of a national coverage agreement with Humana for its CNSide diagnostic assay. Many are buzzing about how this deal expands access to 16 million more individuals, bringing total coverage to 67 million in the US. This has sparked optimism about the company’s growth in the cancer diagnostics space.
Nasdaq Compliance Extension: Another hot topic on X is the 180-day extension granted by Nasdaq for PSTV to meet the minimum bid price requirement. Discussions highlight relief that no immediate reverse stock split is needed, with a deadline set for May 2026. Some users are curious about the long-term implications for the stock’s stability.
Note: This discussion summary was generated from an AI condensation of post data.
Plus Therapeutics Insider Trading Activity
Plus Therapeutics insiders have traded $PSTV stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $PSTV stock by insiders over the last 6 months:
- ROBERT P LENK purchased 110,000 shares for an estimated $53,779
- ANDREW JOHN HUGH MACINTYRE SIMS (Chief Financial Officer) purchased 20,000 shares for an estimated $10,200
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Plus Therapeutics Hedge Fund Activity
We have seen 18 institutional investors add shares of Plus Therapeutics stock to their portfolio, and 13 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 1,414,286 shares (+4346.2%) to their portfolio in Q3 2025, for an estimated $966,947
- ALTIUM CAPITAL MANAGEMENT LLC added 918,914 shares (+inf%) to their portfolio in Q3 2025, for an estimated $628,261
- GEODE CAPITAL MANAGEMENT, LLC added 762,074 shares (+1489.1%) to their portfolio in Q3 2025, for an estimated $521,029
- UBS GROUP AG added 536,236 shares (+611.9%) to their portfolio in Q3 2025, for an estimated $366,624
- BLACKROCK, INC. added 462,429 shares (+6644.1%) to their portfolio in Q3 2025, for an estimated $316,162
- STATE STREET CORP added 341,893 shares (+inf%) to their portfolio in Q3 2025, for an estimated $233,752
- NORTHERN TRUST CORP added 265,489 shares (+inf%) to their portfolio in Q3 2025, for an estimated $181,514
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Plus Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $PSTV in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Ascendiant Capital issued a "Buy" rating on 11/21/2025
- D. Boral Capital issued a "Buy" rating on 11/20/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/03/2025
- Maxim Group issued a "Buy" rating on 08/18/2025
To track analyst ratings and price targets for Plus Therapeutics, check out Quiver Quantitative's $PSTV forecast page.
Plus Therapeutics Price Targets
Multiple analysts have issued price targets for $PSTV recently. We have seen 4 analysts offer price targets for $PSTV in the last 6 months, with a median target of $4.0.
Here are some recent targets:
- Edward Woo from Ascendiant Capital set a target price of $19.0 on 11/21/2025
- Jason Kolbert from D. Boral Capital set a target price of $5.0 on 11/20/2025
- Sean Lee from HC Wainwright & Co. set a target price of $2.0 on 11/03/2025
- Jason McCarthy from Maxim Group set a target price of $3.0 on 08/18/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
